Megestrolacetaat Focus

Megestrol acetate, the active ingredient in Megestrolacetaat Focus, is a progestin presented as an oral formulation for systemic use. It is employed to stimulate appetite in patients with cachexia related to AIDS or cancer and to treat hormone‑responsive breast and endometrial cancers.

GNH USA supplies Megestrolacetaat Focus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with robust quality assurance and regulatory compliance. The company ensures consistent batch release and traceability across all markets.

Megestrol acetate is used in conditions where hormonal modulation or appetite stimulation is required, primarily in oncology and HIV‑related cachexia.

- Cachexia associated with AIDS: improves appetite and promotes weight gain in patients with HIV‑related wasting. - Cachexia associated with cancer: helps restore nutritional status and body mass in oncology patients. - Breast cancer: used as part of hormonal therapy for hormone‑sensitive tumors. - Endometrial cancer: employed in the management of advanced or recurrent disease.

Megestrol acetate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Weight gain: excess caloric retention and fluid accumulation. - Edema: peripheral swelling, especially in the lower extremities. - Nausea or vomiting: gastrointestinal discomfort. - Fatigue: generalized tiredness or reduced energy. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: signs of cortisol deficiency. - Hepatotoxicity: abnormal liver function tests or hepatitis. - Hyperglycemia: elevated blood glucose levels, particularly in diabetic patients.

Before initiating therapy, clinicians should assess individual risk factors and monitor for potential complications.

- Assess baseline weight and nutritional status: document changes during treatment. - Evaluate thrombotic risk: consider prophylaxis in patients with history of clotting disorders. - Monitor blood glucose: especially in patients with diabetes or metabolic syndrome. - Check liver function tests periodically: detect early signs of hepatotoxicity. - Review concomitant hormone therapies: avoid additive hormonal effects. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Megestrol acetate can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce megesterol levels. - Glucocorticoids: additive effects on adrenal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: potential for hyperglycemia, requiring dose adjustment. - Antihypertensives: fluid retention may blunt blood pressure control. - Hormonal contraceptives: possible reduction in contraceptive efficacy.